BioSpace News Archive

-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome --

Highlights: International study will be conducted in a laboratory at a leading academic institution in the U.S. to evaluate anti-viral activity of RECCE ® 327 and new antiviral formulation RECCE ® 529 Expanded program utilizing Centers for Disease Control (CDC) SARS-CoV-2 clinical isolate SARS-Related Coronavirus 2, Isolate USA-WA1/2020 Preliminary data anticipated September 2020 SYDNEY, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Compa

First Prospective Multi-Center Study Evaluating Same Day Discharge for Patients Undergoing Cardiac Ablation Procedures for Atrial Fibrillation

Domain Associates and Catalys Pacific today announced the launch of Exalys Therapeutics Inc. with the closing of a $15 million Series A financing and the licensing of a platform of next-generation EP4 receptor antagonists from Eisai Co. Ltd. in Japan.

Biocept, Inc. announces that Institutional Shareholder Services and Glass Lewis & Co. both have recommended that stockholders vote in favor of Biocept’s proxy proposal to authorize a reverse stock split of Biocept’s common stock, as further described in Biocept’s Proxy Statement for its 2020 Annual Meeting of Stockholders.

Lincotek Additive, the Additive Solutions Provider, has recently completed its brand new, state-of-the-art Additive Production Center for medical devices in its Trento facility, by installing a new high-vacuum furnace and a validated heat treatment process, specifically designed for 3D-printed titanium parts.

A Biotechnology Industry Leader and Internationally Known Vitreo-Retinal Specialist with Notable Expertise in Pharmaceuticals for Age-Related Macular Degeneration and Ocular Gene Therapy – NEW YORK--( BUSINESS WIRE )-- IVERIC bio, Inc. (NASDAQ: ISEE) announced today the election of Mark S. Blumenkranz, M.D., M.M.S., HJ Smead Professor Emeritus of Ophthalmology at Stanford University, to its Board of Directors, effective as of July 15, 2020. D

FDA stated that the nonclinical program was appropriate to support initiating studies in COVID-19 patients

Chiesi Group reports €1,992.81 million in revenue, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption. The report, which is based on the approach of renowned U.S. economist and essayist Jeffrey Sachs, includes Chiesi’s environmental, social and economic performance. The four cornerstones of the document are Processes, Products and Patients, Global Value Chain and Corporate Citizenship. CARY, N.C., July 16, 2020 (GLO

Multi-center dose escalation and expansion study will assess safety, tolerability and preliminary efficacy of treatment with ONCR-177 alone and in combination with Merck’s KEYTRUDA® (pembrolizumab)